Mechanism of Action
Astaxanthin neutralizes reactive oxygen species (unstable molecules that damage cells) directly in the lipid phase of membranes. Unlike vitamin C, which operates in aqueous environments, it acts where peroxidation reactions occur.
A free radical attacking a membrane fatty acid triggers a chain reaction: each oxidized lipid damages the next. Astaxanthin interrupts this propagation by trapping the radical before it spreads. In the laboratory, it thereby preserves membrane fluidity, a parameter essential for proper receptor function and nutrient transport across the cell. These mechanisms are described in cells and experimental models; on their own they do not establish a benefit measured in humans.
Key Benefits
- Moderate
In two controlled trials in healthy adults selected for their skin type, the UV dose needed to trigger redness increased more with astaxanthin than with placebo: 4 mg per day for nine weeks, then 6 mg per day for eight weeks. The difference concerns the increase, not the level reached, and it represents about one step on the measurement scale. Trials of 22 and 43 participants, measured under controlled laboratory exposure.
- Emerging
In a trial in 61 adults aged 25 to 60, non-obese, without diabetes or hypertension and with fasting triglycerides of 120 to 200 mg/dL, 6 mg per day for twelve weeks was associated with higher HDL cholesterol — about fifteen participants per group.
Dosage & Forms
Astaxanthin exists in several forms: synthetic (derived from petrochemistry), yeast-derived (Phaffia rhodozyma) and extracted from the microalga Haematococcus pluvialis. The algal form has the most documented bioavailability profile in humans, with a predominance of the all-trans isomer.
The documented effective doses are low. The redness threshold was measured at 4 then 6 mg per day, HDL cholesterol at 6 mg per day. The condition of use applicable to adults in the European Union is 8 mg per day; it is a safety limit, not a target dose, and no human data show that a higher dose delivers more.
As astaxanthin is fat-soluble, its absorption is enhanced by a meal containing lipids. Microencapsulated forms disperse better in aqueous media, but no human study shows that they make a meal unnecessary.
In the Singular Formula
Inclusion rationale
Astaxanthin belongs to the carotenoid family (plant pigments), which the human body does not make itself. In healthy adults, controlled trials measure a rise above placebo in the amount of ultraviolet light needed to redden the skin. That measurement is made under ultraviolet exposure conducted in a laboratory. That result, measured in humans, earns its place in the formula.
Selected form
Red carotenoid pigment extracted from Haematococcus pluvialis microalgae, one of the most concentrated natural sources of astaxanthin. This encapsulated form is water-dispersible: astaxanthin, fat-soluble in its natural state, is carried by a modified corn starch matrix that allows homogeneous dispersion in aqueous media. To date, no published human study compares the absorption of this form with that of the oils and oleoresins used in the trials. A blend of natural tocopherols protects the pigment from oxidation within this matrix. The guaranteed assay covers total free astaxanthin, the sum of its isomers. The all-trans isomer is predominant at batch control.
Composition and Origin
Origin : Plant (Haematococcus pluvialis microalga, on modified corn starch).
Allergens contained : None.
Allergens as traces : None.
Allergens above are declared under European Union regulations. The label of the delivered product carries the declaration applicable to your country of delivery.
Formula dosage
0 to 6 mg.
Dose expressed as pure active substance, excluding excipients and carriers of the raw material.
Synergies in the formula
Linked Biomarkers
Safety & Precautions
Novel Food status was granted by the European Union for Haematococcus pluvialis oleoresin, with a condition of use set at 8 mg per day for adults (Implementing Regulation (EU) 2023/1581). The 2020 EFSA opinion supports this adult window. This is a safety limit, not an efficacy dose. Published human trials run from four to sixteen weeks and report no toxicity signal within that window.
Astaxanthin does not convert to vitamin A, eliminating the risk of hypervitaminosis A even at high doses.
Supplementation is not recommended during pregnancy and breastfeeding due to insufficient data.
The main precaution concerns vitamin K antagonist anticoagulants such as warfarin. A published case reports a sharp rise in a coagulation parameter in a person on that treatment. Preclinical work describes a fall in vitamin K-dependent clotting factors. Singular therefore removes astaxanthin from the formula as soon as such treatment is declared. As a precaution, it is also removed in cases of direct oral anticoagulant, antiplatelet agent, or a clotting disorder. It is also set aside where an ongoing anticancer treatment is declared.
An orange coloration of stools is possible and without consequence.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Ito N et al. | 2018 | Randomised Controlled Trial | Nutrients | View on PubMed |
The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial Randomized, double-blind, placebo-controlled parallel-group trial, 4 mg per day for nine weeks. 23 participants enrolled, 22 analysed, skin phototypes II and III, aged 30 to 56. The change in redness threshold from baseline was significantly greater with astaxanthin; the threshold reached after nine weeks did not differ significantly between groups. Mean effect of about 5 mJ/cm². The required sample size had been set from hydration data, not redness-threshold data. Study funded by an industry sponsor. | ||||
| Wu D et al. | 2020 | Meta-analysis | International Journal of Vitamin and Nutrition Research | View on PubMed |
Effects of Astaxanthin Supplementation on Oxidative Stress Meta-analysis of 9 randomized trials on oxidative-stress markers: the signal appears only from 20 mg per day upwards, more than twice the 8 mg per day adult limit applicable in the European Union, and is not sustained at twelve weeks. The authors conclude that the antioxidant effect in humans remains unclear. The direct trial at 2 or 8 mg per day showed nothing on this type of marker. | ||||
| Yoshida H et al. | 2010 | Randomised Controlled Trial | Atherosclerosis | View on PubMed |
Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia Randomized placebo-controlled trial in 61 adults aged 25 to 60, non-obese, without diabetes or hypertension, selected for fasting triglycerides of 120 to 200 mg/dL. Four arms: placebo, 6, 12 and 18 mg per day for twelve weeks. Higher HDL cholesterol at 6 and 12 mg, but not at 18 mg; lower triglycerides at 12 and 18 mg. The 12 and 18 mg doses exceed the adult limit applicable in Europe. A synthesis pooling placebo-controlled trials does not find a significant effect on HDL. | ||||
| Tominaga K et al. | 2012 | Clinical Trial | Acta Biochimica Polonica | View on PubMed |
Cosmetic benefits of astaxanthin on humans subjects Article combining two studies: an open-label study without a control group in 30 women, pairing 6 mg taken by mouth with a topical application, and a randomized double-blind placebo-controlled trial in 36 healthy men, at 6 mg per day by mouth for six weeks, where crow's-feet wrinkles, elasticity and transepidermal water loss are reported as improved, with no figures and no published between-group comparison. | ||||
| Davinelli S et al. | 2018 | Review | Nutrients | View on PubMed |
Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review General review of astaxanthin and the skin: it surveys possible photoprotective, antioxidant and anti-inflammatory mechanisms. It does not demonstrate photoprotection; the only controlled result concerns the minimal erythemal dose under experimental UV exposure. | ||||
| Fakhri S et al. | 2018 | Review | Pharmacological Research | View on PubMed |
Astaxanthin: A Mechanistic Review on Its Biological Activities and Health Benefits Mechanistic review detailing the biological pathways described in the laboratory for astaxanthin, on lipid oxidation and lipid metabolism. These pathways do not establish a benefit in humans. | ||||
| Ambati RR et al. | 2014 | Review | Marine Drugs | View on PubMed |
Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications--A Review Comprehensive review of astaxanthin sources, extraction and biological activities, documenting its properties and applications. | ||||